Wave Life Sciences starts Phase 2a combo trial of WVE-007 with tirzepatide

September 23, 2026 7:30 AM

Wave Life Sciences Ltd. (Nasdaq: WVE) announced the initiation of a Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found